← 홈

프로그램 비교

타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일

현재 선택: 1개 · 임상 갱신 필요 1개

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

프로그램 선택

API CSV15행 · 1개 프로그램
OverviewPK/PDToxicologyClinical

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
CGTStandard DatabasestalePhase 3
enfuvirtide (enfuvirtide)
Hoffmann-La Roche·HIV Infections
31 trials·t½ 27 h
Overview
Program
enfuvirtide
Overview
Company
Hoffmann-La Roche
Overview
Modality
CGT
Overview
Target
HIV Infections
Overview
Indication
HIV Infections
Overview
Phase
PHASE_3
Overview
Status
ACTIVE
Overview
Content status
Standard Database
Overview
Data Confidence
Data Confidence · Medium
Overview
Development Signal
Development Signal · Emerging
Overview
Approval status
Investigational
PK/PD
Half-life
27 h
Toxicology
Major finding
Next-generation antiviral peptides: AI-driven design, translational delivery platforms, and future therapeutic directions.. Antiviral peptides (AVPs) are emerging as next-generation therapeutics due to their broad-spectrum activity, low toxicity, and ability to overcome drug resistance. The objective of this review is to provide an integrated perspective on AVP research, with particular emphasis o…
Clinical
Safety signal
Next-generation antiviral peptides: AI-driven design, translational delivery platforms, and future therapeutic directions.. Antiviral peptides (AVPs) are emerging as next-generation therapeutics due to their broad-spectrum activity, low toxicity, and ability to overcome drug resistance. The objective of this review is to provide an integrated perspective on AVP research, with particular emphasis o…
Clinical
Program phase
PHASE_3